Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lipid Metabolism Disorders: early-phase trial registry
1 of 3 indexed Lipid Metabolism Disorders trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Lipid Metabolism Disorders: 3 US clinical trials tracked, 1 recruiting.
Lipid Metabolism Disorders is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Catabasis Pharmaceuticals, running 1 of these trials.
Enrollment posture brief
Registry condition lipid-metabolism-disorders
OPEN 1 | RECR 33% | LATE 0 | EARLY 2 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Lipid Metabolism Disorders lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lipid Metabolism Disorders on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lipid Metabolism Disorders is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Differential Thrombogenesis by EPA and DHA Mediated by HDL
The Miriam Hospital
NCT06494488
Identification of Novel Skeletal Muscle-derived Factors That Promote Lipid Oxidation (Columbus)
AdventHealth Translational Research Institute
NCT01911091
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
Catabasis Pharmaceuticals
NCT01968720
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Lipid Metabolism Disorders records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lipid Metabolism Disorders trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lipid Metabolism Disorders page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Lipid Metabolism Disorders trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Catabasis Pharmaceuticals sponsors the most Lipid Metabolism Disorders trials on record, review their full trial history before evaluating a specific study. See Catabasis Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lipid Metabolism Disorders condition card totals 3 registered trials; most-linked intervention CAT-2003; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.